GlassScriptPhysician profile
Pierre Thomas Martin
NPI 1225010143
$5,031.91
in general payments reported to CMS, 2019-2025
13 companies · $554 in 2025
The $554 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $158 · 2020: $117 · 2021: $377 · 2022: $396 · 2023: $1,399 · 2024: $2,032 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,465 · Travel and Lodging: $1,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,465.12 |
| Travel and Lodging | $1,518.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $3,469.14 | 2021-2025 | Inspire |
| Aerin Medical INC. | $450.58 | 2022-2025 | |
| Glaxosmithkline, LLC. | $380.97 | 2019-2025 | Nucala |
| Optinose US, INC. | $193.76 | 2019-2025 | |
| Medtronic, INC. | $151.48 | 2021-2025 | Stealthstation S8 Platform |
| Intersect Ent, INC. | $133.94 | 2019-2021 | |
| Stryker Corporation | $116.91 | 2020 | |
| Ars Pharmaceuticals Operations, INC. | $30.85 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $28.16 | 2022 | |
| Cochlear Americas | $22.11 | 2025 | Baha, Osia Osi300 Implant, Cochlear Nucleus Ci632 Cochlear Implant With Slim Modiolar Electrode |
| Novartis Pharmaceuticals Corporation | $22.09 | 2021 | |
| Tactile Systems Technology INC | $17.00 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $14.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pierre Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.